Special Populations

  • Brian V. Reamy
  • Brian K. Unwin
  • Christopher G. Jarvis


This elderly population is a high-risk, problem-prone group that often has multiple comorbidities requiring a comprehensive and caring approach in management to prevent disease and disability. It is also relevant to discuss this population subset because the elderly are the fastest growing demographic subgroup in the U.S. population.

In 2000, 40% of all deaths in Americans over the age of 65 were linked to hyperlipidemia. Coronary artery disease mortality and morbidity are highest among elderly men and women, with more than 80% of the deaths from coronary heart disease (CHD) occurring in individuals over the age of 65 [1]. Reducing the death or resultant disability related to these conditions is of obvious importance and benefit to individual patients and to our nation.

Pharmacologic therapy for hyperlipidemia in elderly patients is expensive for those seniors on limited incomes or with significant drug cost shares. The number of medications and multiple comorbidities common in...


Statin Therapy Anabolic Steroid Elite Athlete Bile Acid Sequestrant High Density Lipoprotein Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Lerner DJ, Kanner WK. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26 year follow-up of the Framingham population. Am Heart J 1986;111:383–390.PubMedCrossRefGoogle Scholar
  2. 2.
    Merck Institute of Aging and Health. The state of aging and health in America 2004. Washington, DC: Merck Institute of Aging and Health (MIAH), 2004:1.Google Scholar
  3. 3.
    Katzel LI, Goldberg AP. Dyslipoproteinemia. In: Hazzard WR, Blass JP, Ettinger WH, et al. (eds) Principles of geriatric medicine and gerontology, 4th edn. New York: McGraw-Hill, 1999:1013–1028.Google Scholar
  4. 4.
    Beck L. Aging changes in renal function. In: Hazzard WR, Blass JP, Ettinger WH, et al. (eds) Principles of geriatric medicine and gerontology, 4th edn. New York: McGraw-Hill, 1999.Google Scholar
  5. 5.
    Weverling-Rijnsburger AW, Blauw GJ, Lagaay AM, et al. Total cholesterol and risk of mortality in the oldest old. Lancet 1997;350(9085):1119–1123.PubMedCrossRefGoogle Scholar
  6. 6.
    Shipley MJ, Pocock SJ, Marmot MG. Does plasma cholesterol concentration predict mortality from coronary heart disease in elderly people? 18-year follow up in Whitehall study. BMJ 1991;303:89–92.PubMedCrossRefGoogle Scholar
  7. 7.
    Fouts M, Hanlon J, Pieper C, et al. Identification of elderly nursing home residents at high risk for drug related problems. Consult Pharmacol 1997;12:1103–1111.Google Scholar
  8. 8.
    Fink DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults. Arch Intern Med 2003;163:2716–2722.CrossRefGoogle Scholar
  9. 9.
    Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 2004;291(15):1864–1870.PubMedCrossRefGoogle Scholar
  10. 10.
    Whincup PH, Emberson JR, Lennon L, et al. Low prevalence of lipid lowering drug use in older men with established coronary heart disease. Heart 2002;88:25–29.PubMedCrossRefGoogle Scholar
  11. 11.
    Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID Trial. Ann Intern Med 2001;134:931–940.PubMedGoogle Scholar
  12. 12.
    Collins R, Armitage J, Parish S, Sleigh P, Peto R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361: 2005–2016.PubMedCrossRefGoogle Scholar
  13. 13.
    Downs JR, Clearfield M, Weis S, et al., for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279(20):1615–1622.PubMedCrossRefGoogle Scholar
  14. 14.
    Colhoun HM, Betteridge DJ, Durrington PN, et al., on behalf of the CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685–696.PubMedCrossRefGoogle Scholar
  15. 15.
    Shepherd J, Blauw GJ, Murphy M, et al., on behalf of the PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623–1630.PubMedCrossRefGoogle Scholar
  16. 16.
    Shepherd J, Blauw GH, Murphy M, et al., on behalf of the PROSPER study group. Preventing the next event in the elderly: the PROSPER perspective. Atherosclerosis Suppl 2003;4: 17–22.CrossRefGoogle Scholar
  17. 17.
    Tonmin AM, Eckerman S, White H, et al. Cost effectiveness of cholesterol lowering therapy with pravastatin in patients with previous coronary syndromes aged 65 to 74 years compared with younger patients. Am Heart J 2006;151:1305–1312.CrossRefGoogle Scholar
  18. 18.
    American Heart Association. Heart Disease and Stroke Statistics: 2005 Update. Accessed 07/07/06.
  19. 19.
    Mosca L, Appel LJ, Benjamin EJ, et al. Evidence based guidelines for cardiovascular disease prevention in women. Circulation 2004;109:672–693.PubMedCrossRefGoogle Scholar
  20. 20.
    Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557–1565.PubMedCrossRefGoogle Scholar
  21. 21.
    Anonymous. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking: a preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. JAMA 1990;264:3018–3024.Google Scholar
  22. 22.
    Mahoney LT, Burns TL, Stanford W, et al. Coronary risk factors measured in childhood and young adult life are associated with coronary artery calcification in young adults: the Muscatine Study. J Am Coll Cardiol 1996;27:277–284.PubMedCrossRefGoogle Scholar
  23. 23.
    Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults: the Bogalusa Heart Study. N Engl J Med 1998;338:1650–1656.PubMedCrossRefGoogle Scholar
  24. 24.
    Li S, Chen W, Srinivasan SR, et al. Childhood cardiovascular risk factors and carotid vascular changes in adulthood. JAMA 2003;290:2271–2277.PubMedCrossRefGoogle Scholar
  25. 25.
    NCEP. Highlights of the report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics 1992;89:495–501.Google Scholar
  26. 26.
    Jolliffe CJ, Janssen I. Distribution of lipoproteins by age and gender in adolescents. Circulation 2006;114:1056–1062.PubMedCrossRefGoogle Scholar
  27. 27.
    Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2004;292:331–337.PubMedCrossRefGoogle Scholar
  28. 28.
    de Jongh S, Lilien MR, Op’t Roodt J, et al. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 2002;40:2117–2121.PubMedCrossRefGoogle Scholar
  29. 29.
    Kavey REW, Daniels SR, Lauer RM, et al. AHA guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation 2003;107:1562–1566.PubMedCrossRefGoogle Scholar
  30. 30.
    Howard BV, Lee ET, Cown LD, et al. Rising tide of cardiovascular disease in American Indians. The Strong Heart Study. Circulation 1999;99:2389–2395.Google Scholar
  31. 31.
    Robbins DC, Welty TK, Wang WY, et al. Plasma lipids and lipoprotein concentrations among American Indians: comparison with the US population. Curr Opin Lipidol 1996;7:188–195.PubMedCrossRefGoogle Scholar
  32. 32.
    Welty TK, Lee ET, Yeh J, et al. Cardiovascular disease risk factors among American Indians: the Strong Heart Study. Am J Epidemiol 1995;142:269–287.PubMedGoogle Scholar
  33. 33.
    Wood P, Williams PT, Haskell WL. Physical activity and high density lipoproteins. In: Miller NE, Miller GJ (eds) Clinical and metabolic aspects of high density lipoproteins. Amsterdam: Elsevier, 1984:133–165.Google Scholar
  34. 34.
    Modlinski R, Fields KB. The effect of anabolic steroids on the gastrointestinal system, kidneys, and adrenal glands. Curr Sports Med Rep 2006;5(2):104–109.PubMedGoogle Scholar
  35. 35.
    Glazer G. Atherogenic effects of anabolic steroids on serum lipid levels. Arch Intern Med 1991;151:1925–1933.PubMedCrossRefGoogle Scholar
  36. 36.
    Sullivan ML, Martinez CM, Gennis P, et al. The cardiac toxicity of anabolic steroids. Prog Cardiovasc Dis 1998;41:1–5.PubMedCrossRefGoogle Scholar
  37. 37.
    Rickenlund A, Eriksson MJ, et al. Amenorrhea in female athletes is associated with endothelial dysfunction and unfavorable lipid profile. J Clin Endocrinol Metab 2005;90(3):1354–1359.PubMedCrossRefGoogle Scholar
  38. 38.
    Crouse JR III, Elam MB, Robinson JG, et al. Cholesterol management: targeting a lower low density lipoprotein cholesterol concentration increases ATP-III goal attainment. Am J Cardiol 2006;97(11):1667–1669.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Brian V. Reamy
    • 1
  • Brian K. Unwin
  • Christopher G. Jarvis
  1. 1.Chair and Associate Professor, Department of Family MedicineUniformed Services University of the Health SciencesMaryland

Personalised recommendations